Page 890 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 55 Progress in the Classification of Hematopoietic and Lymphoid Neoplasms 773

6. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World 25. Henopp T, Quintanilla-Martinez L, Fend F, et al: Prevalence of fol-
Health Organization (WHO) classification of myeloid neoplasms and licular lymphoma in situ in consecutively analysed reactive lymph nodes.
acute leukemia: rationale and important changes. Blood 114:937–951, Histopathology 59:139–142, 2011.
2009. 26. Fend F, Cabecadas J, Gaulard P, et al: Early lesions in lymphoid neoplasia:
7. Maciejewski JP, Haferlach T: Introduction: molecular pathogenesis of conclusions based on the Workshop of the XV. Meeting of the European
hematologic malignancies. Semin Oncol 39:9–12, 2012. Association of Hematopathology and the Society of Hematopathology,
8. Anastasi J: The myeloproliferative and overlap, myeloproliferative/ in Uppsala, Sweden. J Hematop 5:169–199, 2012.
myelodysplastic neoplasms. In Hsi E, editor: The myeloproliferative 27. Dhodapkar MV, Sexton R, Waheed S, et al: Clinical, genomic, and
and overlap, myeloproliferative/myelodysplastic neoplasms, St Louis, 2012, imaging predictors of myeloma progression from asymptomatic mono-
Elsevier, p 479. clonal gammopathies (SWOG S0120). Blood 123:78–85, 2014.
9. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific 28. Morgan GJ, Walker BA, Davies FE: The genetic architecture of multiple
inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. myeloma. Nat Rev Cancer 12:335–348, 2012.
N Engl J Med 344:1031–1037, 2001. 29. Kyle RA, Durie BG, Rajkumar SV, et al: Monoclonal gammopathy
10. Tefferi A, Thiele J, Vannucchi AM, et al: An overview on CALR and of undetermined significance (MGUS) and smoldering (asymptomatic)
CSF3R mutations and a proposal for revision of WHO diagnostic cri- multiple myeloma: IMWG consensus perspectives risk factors for
teria for myeloproliferative neoplasms. Leukemia 28:1407–1413, 2014. progression and guidelines for monitoring and management. Leukemia
11. Klampfl T, Gisslinger H, Harutyunyan AS, et al: Somatic mutations of 24:1121–1127, 2010.
calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379– 30. Shim YK, Rachel JM, Ghia P, et al: Monoclonal B-cell lymphocytosis
2390, 2013. in healthy blood donors: an unexpectedly common finding. Blood
12. Nangalia J, Massie CE, Baxter EJ, et al: Somatic CALR mutations in 123:1319–1326, 2014.
myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 31. Cong P, Raffeld M, Teruya-Feldstein J, et al: In situ localization of
369:2391–2405, 2013. follicular lymphoma: description and analysis by laser capture microdis-
13. Elliott MA, Tefferi A: Chronic neutrophilic leukemia 2014: Update section. Blood 99:3376–3382, 2002.
on diagnosis, molecular genetics, and management. Am J Hematol 32. Carvajal-Cuenca A, Sua LF, Silva NM, et al: In situ mantle cell lym-
89:651–658, 2014. phoma: clinical implications of an incidental finding with indolent
14. Chiu A, Orazi A: Mastocytosis and related disorders. Semin Diagn Pathol clinical behavior. Haematologica 97:270–278, 2012.
29:19–30, 2012. 33. Beltran BE, Morales D, Quinones P, et al: EBV-positive diffuse large
15. Jawhar M, Schwaab J, Schnittger S, et al: Additional mutations in SRSF2, b-cell lymphoma in young immunocompetent individuals. Clin Lym-
ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT phoma Myeloma Leuk 11:512–516, 2011.
D816V (+) advanced systemic mastocytosis. Leukemia 30:136–143, 34. Sehn LH, Gascoyne RD: Diffuse large B-cell lymphoma: optimizing
2016. outcome in the context of clinical and biologic heterogeneity. Blood
16. Gotlib J: World Health Organization-defined eosinophilic disorders: 125:22–32, 2015.
2011 update on diagnosis, risk stratification, and management. Am J 35. Scott DW, Wright GW, Williams PM, et al: Determining cell-of-origin
Hematol 86:677–688, 2011. subtypes of diffuse large B-cell lymphoma using gene expression in
17. Stone RM, et al: The multi-kinase inhibitor midostaurin (M) prolongs formalin-fixed paraffin-embedded tissue. Blood 123:1214–1217, 2014.
survival compared with placebo (P) in combination with Daunorubicin 36. Masque-Soler N, Szczepanowski M, Kohler CW, et al: Molecular clas-
(D)/Cytarabine (C) induction (ind), high-dose C consolidation (consol), sification of mature aggressive B-cell lymphoma using digital multiplexed
and as maintenance (maint) therapy in newly diagnosed acute Myeloid gene expression on formalin-fixed paraffin-embedded biopsy specimens.
Leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): Blood 122:1985–1986, 2013.
an international prospective randomized (rand) P-controlled double- 37. Zhang J, Grubor V, Love CL, et al: Genetic heterogeneity of diffuse large
blind Trial (CALGB 10603/RATIFY [Alliance]). Blood 16:2015. ahead B-cell lymphoma. Proc Natl Acad Sci USA 110:1398–1403, 2013.
of print. 38. Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al: Inactivating
18. Pratz K, Levis M: Incorporating FLT3 inhibitors into acute myeloid mutations of acetyltransferase genes in B-cell lymphoma. Nature
leukemia treatment regimens. Leuk Lymphoma 49:852–863, 2008. 471:189–195, 2011.
19. West AH, Godley LA, Churpek JE: Familial myelodysplastic syndrome/ 39. Chambwe N, Kormaksson M, Geng H, et al: Variability in DNA
acute leukemia syndromes: a review and utility for translational investiga- methylation defines novel epigenetic subgroups of DLBCL associated
tions. Ann N Y Acad Sci 1310:111–118, 2014. with different clinical outcomes. Blood 123:1699–1708, 2014.
20. Nacheva EP, Grace CD, Brazma D, et al: Does BCR/ABL1 positive acute 40. Cerchietti L, Leonard JP: Targeting the epigenome and other new strate-
myeloid leukaemia exist? Br J Haematol 161:541–550, 2013. gies in diffuse large B-cell lymphoma: beyond R-CHOP. Hematology Am
21. Konoplev S, Yin CC, Kornblau SM, et al: Molecular characterization Soc Hematol Educ Program 2013:591–595, 2013.
of de novo Philadelphia chromosome-positive acute myeloid leukemia. 41. Ahearne MJ, Allchin RL, Fox CP, et al: Follicular helper T-cells: expand-
Leuk Lymphoma 54:138–144, 2013. ing roles in T-cell lymphoma and targets for treatment. Br J Haematol
22. Arber DA, Hasserjian RP: Reclassifying myelodysplastic syndromes: 166:326–335, 2014.
what’s where in the new WHO and why. Hematology Am Soc Hematol 42. Rodriguez Pinilla SM, Roncador G, Rodriguez-Peralto JL, et al: Primary
Educ Program 2015:294–298, 2015. cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma
23. Xie Y, Pittaluga S, Jaffe ES: The histological classification of diffuse large expresses follicular T-cell markers. Am J Surg Pathol 33:81–90, 2009.
B-cell lymphomas. Semin Hematol 52:57–66, 2015. 43. Loghavi S, Kutok JL, Jorgensen JL: B-acute lymphoblastic leukemia/
24. Tirado CA, Chen W, Garcia R, et al: Genomic profiling using array lymphoblastic lymphoma. Am J Clin Pathol 144:393–410, 2015.
comparative genomic hybridization define distinct subtypes of diffuse 44. Fasan A, Haferlach C, Alpermann T, et al: The role of different genetic
large B-cell lymphoma: a review of the literature. J Hematol Oncol 5:54, subtypes of CEBPA mutated AML. Leukemia 28:794–803, 2014.
2012.